Navigation Links
Prostate cancer: Watchful wait or vaccinate?
Date:1/31/2008

er, colon, kidney and stomach.

The researchers created a prime-boost vaccination scheme using two kinds of vaccines and tested it in 8-week-old mice that were genetically altered to develop prostate cancer later in life. The first vaccine simply delivered a fragment of DNA that coded for PSCA, thus producing an influx of PSCA protein to alert the immune system. The booster shot, given two weeks later, used a modified horse virus to deliver the PSCA gene.

Confronting the immune system in two different ways forces it to mount a strong response, Kast said.

In the experimental group, two of 20 mice developed prostate cancer at the end of one year, and by contrast, all control mice had died of the disease. Researchers found that mice in the experimental group had all developed very small tumors that did not progress. There were tiny nodules of prostate cancer in the mice that were surrounded by an army of immune system cells, Kast said. The vaccination turned the cancer into a chronic, manageable disease.

The vaccination strategy also works with other antigens, Kast says. The researchers recently tried another prostate cancer membrane target and found that after 1.5 years, 65 percent of experimental mice were still alive, and of those that died, the suspected cause was old age.

Crucially, investigators further found that treated mice did not develop autoimmune disease, a side effect that could develop if the vaccine had also targeted PSCA expression in normal cells. Theoretically, the vaccine could produce a response in any tissue that expresses the antigen, but the fact that PSCA is expressed in such low levels in normal tissue may prevent that complication, he said.

Still, studies in humans are needed to ensure autoimmunity does not develop, Kast says.

We feel this is a very promising approach, he said. With just two shots, the vaccine will prime immune cells to be on the lookout for any cell that over-expresses
'/>"/>

Contact: Staci Vernick Goldberg
Staci.goldberg@aacr.org
267-646-0616
American Association for Cancer Research
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Nanomedicine research for prostate cancer supported by $5 million gift
2. Safeway Inc. and PCF to fund landmark prostate cancer research collaboration
3. New genetic variant associated with prostate cancer in African-Americans
4. Leading researchers to reveal comprehensive dos and donts for prostate cancer
5. New prostate cancer research findings
6. University of Minnesota study refutes belief that black men have more aggressive prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2015)... , Feb. 24, 2015 Research and ... the addition of the "Global 2D Gesture ... The analysts forecast the Global ... CAGR of 32.12% over the period 2014-2019 ... in non-traditional sectors is one of the major ...
(Date:2/19/2015)... DUBLIN , Feb .19, 2015 Research ... announced the addition of the "Military Electro-Optical ... by Sensor Technology, by Platform - Forecast to ... The military electro-optical/infrared systems market is expected ... a CAGR of 7.71%. This report ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3ACT Genomics Raises $8 Million in its First Private Funding Round 2
... the mechanical strength of cancer cell mucus layers provides ... suggests why some cancer cells are more resistant to ... of engineering at Northeastern University, Boston, Mass. ... protect against infection. Cancer cells, however, produce far more ...
... March, 2011 A recent special edition of the journal ... of the British Mycological Society, features a total of 76 ... cell biology movies ever published. The movies were produced by ... is a renowned researcher in the field of fungal cell ...
... A Purdue University scientist,s nanopolymer would make it easier ... of a widely used class of cancer inhibitors. ... chemistry and a member of the Purdue Center for ... can be used to determine whether cancer drugs have ...
Cached Biology News:Breaking the mucus barrier unveils cancer cell secrets 2Purdue startup hopes to change the way we test cancer drugs 2
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
(Date:2/26/2015)... Feb. 26, 2015   Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... President and Chief Executive Officer of Regulus, will present ... th Annual Healthcare Conference on Wednesday, March 4, ... held at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)...  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), the ... hair rejuvenation, has announced that it has selected ... investor relations and strategic communications. ... diversification strategies – and we need to communicate ... Ali Kharazmi CEO of NuGene when announcing this ...
(Date:2/26/2015)... Innovation is more urgent than ever. Radical ... the world and transforming global markets in industry ... health care, disruption is constantly underway. , As ... shake the foundations of established business models, large-scale ... survive the next wave of mega-change. , This ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2
... (Nasdaq: OREX ), a biopharmaceutical company focused on ... third quarter of 2011. For the three months ended September ... or $0.10 per share, as compared to a net loss ... quarter of 2010. As of September 30, 2011, Orexigen had ...
... an open-source, web-based platform for data-intensive biomedical and ... "cloud computing" resource. A team of researchers including ... molecular biology at Penn State University; Kateryna Makova, ... and James Taylor from Emory University, developed the ...
... plastics could be produced using an intricate chemical process ... 80,000 times smaller than a hair,s breadth ... could give materials exceptional versatility. By weaving threads ... at the University of Edinburgh have created the building ...
Cached Biology Technology:Orexigen® Therapeutics Reports Third Quarter Financial Results 2Orexigen® Therapeutics Reports Third Quarter Financial Results 3Orexigen® Therapeutics Reports Third Quarter Financial Results 4Orexigen® Therapeutics Reports Third Quarter Financial Results 5Galaxy DNA-analysis software is now available 'in the cloud' 2Galaxy DNA-analysis software is now available 'in the cloud' 3Tying atomic threads in knots may produce material benefits 2
...
... The organic acid analysis ... of six organic salts; molecular ... 294. This standard is provided ... HPX-87H column and the organic ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
Biology Products: